Skip to content
sellWeak cluster of 310b5-1 plan

Nicole LaBrosse sold $1.5M of HALO

SVP, CHIEF FINANCIAL OFFICER at HALOZYME THERAPEUTICS, INC.. 20,000 shares at an average of $75.71, traded Sep 10, 2025, filed Sep 11, 2025.

Warning score
37
Value
$1.5M
20,000 shares
Holdings after
24,306
-45% from before
From 52-week low
+78%
low $42.57, close $75.80
From 52-week high
-0%
high $76.07, as of Sep 10, 2025

Score components

  • Role
    CFO
    +22
  • Trade size
    $1.5M at market
    +25
  • Share of holdings sold
    Sold 45% of holdings
    +10
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

HALOOct 9, 2026 · close 110.42
Since filing Sep 11, 2025: +42.4%SPY +20.0% · excess +22.4%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001415889-25-024295, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Sep 10, 2025MOption exercise
Common Stock10b5-1
+11,271$12.07$136k43,171Sep 11, 2025
Sep 10, 2025MOption exercise
Common Stock10b5-1
+1,135$12.49$14k44,306Sep 11, 2025
Sep 10, 2025SOpen-market sale
Common Stock10b5-1
-6,760$75.29$509k37,546Sep 11, 2025
Sep 10, 2025SOpen-market sale
Common Stock10b5-1
-13,240$75.93$1.0M24,306Sep 11, 2025
Sep 10, 2025MOption exercise
Option to Purchase Common Stockderivative10b5-1
-11,271$0.00$00Sep 11, 2025
Sep 10, 2025MOption exercise
Option to Purchase Common Stockderivative10b5-1
-1,135$0.00$0812Sep 11, 2025

Related signals

Other insiders at HALOZYME THERAPEUTICS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
23Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$6.6M
60,000 shares
-8%
22Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Matthew L. Posard
director
$568k
5,230 shares
-9%
33Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Matthew L. Posard
director
$2.0M
18,996 shares
-24%
23Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$6.4M
60,000 shares
-8%
44Moderate
HALOsell 3
HALOZYME THERAPEUTICS, INC.
Cortney Caudill
SVP, CHIEF OPERATING OFFICER
$278k
4,263 shares
-25%
10Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Bernadette Connaughton
director
$59k
829 shares
-2%
23Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$1.1M
16,569 shares
-2%
21Weak
HALOsell 310b5-1
HALOZYME THERAPEUTICS, INC.
Bernadette Connaughton
director
$137k
2,000 shares
-4%
30Weak
HALOsell 310b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$4.2M
60,000 shares
-8%
30Weak
HALOsell 310b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$4.3M
60,000 shares
-8%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Nicole LaBrosse sold $1.5M of HALO | InsiderTell